Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS‐CoV‐2 neutralizing activity of sera

Autor: David Navarro, Lorena Forqué, Clara Francés-Gómez, Victor Latorre, Ignacio Torres, Ron Geller, Josep Ferrer, Jesús Rodríguez-Díaz, Arantxa Valdivia, Carlos Solano de la Asunción, Dixie Huntley, Estela Giménez, Roberto Gozalbo-Rovira, Javier Buesa, Rosa Costa
Přispěvatelé: Generalitat Valenciana, Consejo Superior de Investigaciones Científicas (España), Navarro, David, Banco Santander, Navarro, David [0000-0003-3010-4110]
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Green Fluorescent Proteins
Antibodies
Viral
Neutralizing antibodies
Neutralization
SARS‐CoV‐2
Green fluorescent protein
03 medical and health sciences
COVID-19 Testing
0302 clinical medicine
COVID‐19
Virology
Lateral flow 16 immunochromatographic assays
Humans
Medicine
Immunochromatographic Assays
030212 general & internal medicine
Neutralizing antibody
Research Articles
Immunoassay
biology
business.industry
SARS-CoV-2
COVID-19
biology.organism_classification
Antibodies
Neutralizing
Titer
Infectious Diseases
Immunoglobulin M
Vesicular stomatitis virus
Immunoglobulin G
Spike Glycoprotein
Coronavirus
biology.protein
lateral flow immunochromatographic assays
030211 gastroenterology & hepatology
Lteral flow immunochromatographic assays
Antibody
business
Research Article
Zdroj: Journal of Medical Virology
Digital.CSIC. Repositorio Institucional del CSIC
instname
Popis: Purpose: Assessment of commercial SARS-CoV-2 immunoassays for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody (NtAb) titers. Patients and Methods: Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP) reporter-based pseudotyped neutralization assay (vesicular stomatitis virus coated with SARS-CoV-2 spike protein) was used. Test line intensity was scored using a 4-level scale (0 to 3+). Results: Overall sensitivity of LFIC assays was 91.1% for the Wondfo SARS-CoV-2 Antibody test, 72.2% for the INNOVITA 2019-nCoV IgG, 85.6% for the INNOVITA 2019-nCoV IgM and 92.2% for the NtAb assay. Sensitivity increased for all assays in sera collected beyond day 14 after symptoms onset (93.9%, 79.6%,93.9% and 93.9%, respectively). Reactivities equal to or more intense than the positive control line (≥2+) in the Wondfo assay had a negative predictive value of 100% and a positive predictive value of 96.4% for high NtAb50 titers (≥1/160). Conclusions: Our findings support the use of LFIC assays evaluated herein, particularly the Wondfo test, for COVID-19 diagnosis. We also find evidence that these rapid immunoassays can be used to predict high SARS-CoV-2-S NtAb50 titers.
This work was supported by Valencian Government grant IDIFEDER/2018/056 to JRD, Generalitat Valenciana grant Covid_19-SCI to RG-R, Spanish National Research Council grant CSIC-COV19-082 and Fondo Supera Covid-19 grant BlockAce to RG-R
Databáze: OpenAIRE
Externí odkaz: